FDA approves Crysvita for treating tumour-induced osteomalacia
pharmafile | June 19, 2020 | News story | Medical Communications | FDA, FDA approvals
The FDA has approved Crysvita (burosumabtwza) injection to treat patients over two years old with tumour-induced osteomalacia (TIO).
This is a rare disease characterized by the development of tumours that cause weakened and softened bones through releasing a peptide hormone-like substance known as FGF23 that lowers phosphate levels.
Two studies evaluated the safety and efficacy of Crysvita and tested 27 patients, where the participants received the injection every four weeks. In the first study, half of patients received normal phosphate levels through to week 24 and maintained normal or near normal phosphate levels through to week 144. The results of bone scans for patients suggested healing of the bone lesions related to TIO.
In the second study, 69% of participants achieved normal levels through to week 24, and maintained normal or near normal phosphate levels through to week 88.
Dr Theresa E. Kehoe, Acting Director of the Division of General Endocrinology, said: “Treatment for TIO focuses on identifying and removing the tumor that causes the disease. However, when that is not possible, Crysvita can help increase the levels of phosphate in the blood. As the first FDA-approved therapy to treat this debilitating disease, today’s action is an important step in finding treatment options for patients living with TIO whose tumor cannot be found or removed.”
Crysvita was previously approved by the FDA to treat adults and children with X-linked hypophosphatemia.
Conor Kavanagh
Related Content
MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance
Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational …
Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation
Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary …
Johnson & Johnson submits robotic surgical system for De Novo classification
Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De …
